Arrowstreet Capital Limited Partnership Raises Position in Genmab A/S Sponsored ADR $GMAB

Arrowstreet Capital Limited Partnership grew its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 152.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,454,378 shares of the company’s stock after acquiring an additional 2,084,966 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.54% of Genmab A/S worth $71,367,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Level Four Advisory Services LLC grew its stake in Genmab A/S by 24.8% during the 2nd quarter. Level Four Advisory Services LLC now owns 64,925 shares of the company’s stock worth $1,341,000 after purchasing an additional 12,888 shares in the last quarter. Capital Fund Management S.A. boosted its stake in shares of Genmab A/S by 110.7% in the 2nd quarter. Capital Fund Management S.A. now owns 226,584 shares of the company’s stock valued at $4,681,000 after buying an additional 119,061 shares during the period. AlphaCore Capital LLC purchased a new position in shares of Genmab A/S in the 2nd quarter valued at about $44,000. Brandywine Global Investment Management LLC grew its position in shares of Genmab A/S by 1.6% during the second quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock worth $36,047,000 after buying an additional 27,372 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Genmab A/S by 17.0% during the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock worth $19,282,000 after buying an additional 135,814 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Truist Financial reaffirmed a “buy” rating and issued a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Tuesday, September 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Finally, Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $39.75.

Genmab A/S Stock Up 1.1%

Shares of GMAB stock opened at $32.02 on Friday. The stock’s 50-day moving average price is $30.78 and its 200 day moving average price is $25.83. The stock has a market capitalization of $20.57 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 1.65 and a beta of 0.90. Genmab A/S Sponsored ADR has a 52-week low of $17.24 and a 52-week high of $33.65.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. Analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.